OM · Outset Medical, Inc.
Market Cap
$57.33M
Shares
18.80M
Volume · Oct 5
203.09K
Avg daily vol (3M)
156.94K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.10
Open$3.96
Day$3.85–4.16
52W close$2.96–15.81
Avg vol 30d176K
Short int890K · 4.7% float · 6.2d
Short vol51%
Last earningsAug 6, 2026
DataSep 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 1, 2026
Est · unconfirmed
· in 4 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$117.80M
Trailing 12 months
Net income (TTM)
−$74.29M
Trailing 12 months
Revenue growth YoY
+0.7%
Year over year
Operating margin
-56.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-67.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.9%
Year over year · more shares
Price change (1Y)
-71.9%
Trailing year
Short interest
4.7%
Latest settlement · 6.2 days to cover
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Outset Medical reiterated full-year 2026 revenue guidance of $125-$130 million, reported Q2 revenue of $31.6 million (up 1% YoY), signed a three-year, $40 million HCA refresh agreement, and delivered non-GAAP gross margin of 42.2%, up more than 380 basis points year-over-year.
Bullish
- + Signed a three-year, $40 million refresh agreement with HCA Healthcare, providing contracted backlog through 2028 new
- + Non-GAAP gross margin expanded to 42.2%, up over 380 basis points year-over-year, on track toward a 50% company-wide gross margin milestone new
- + Service and other gross margin was 33.4%, up over 2,400 basis points year-over-year
- + Cash use of $9.5 million in Q2 keeps the company on track to use less than $40 million for full-year 2026 new
Bearish
- − Consumable revenue declined 12% year-over-year against a double-digit growth comparison in the prior year new
- − Product revenue declined 5% year-over-year against a challenging prior-year growth comparison new
- − Product gross margin was 46.1%, down about 280 basis points year-over-year due to a higher mix of console sales within product revenue new
- − Net loss was $18.0 million for the quarter, with the company still operating at a loss on a path to profitability new
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
+4%
above
RSI (14)
66
neutral
MACD trend
Positive
52-week position
9%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+14%
trailing
6-month return
−6%
trailing
YTD return
+11%
this year
Relative strength
−17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +18 funds added
Insider flow
Accumulating
Net +$823.7K over 90 days · 75% sells
Short interest
Falling
4.73% of float · ▼ -1.3% MoM · 6.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
92 holders — mid 3-yr range
Squeeze score
84
high risk · 0–100
Fundamentals
Revenue growth
+5%
Y/Y
Gross margin
39%
expanding
EPS growth
+85%
Y/Y
Free cash flow
$-47.1M
Balance sheet
$61.2M
net debt
Quant / Vol
risk profile
Volatility
104%
annualized · 1-yr
Max drawdown
−81%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Revenue
· 2026
$125M – $130M
prior FY $119.48M
midpoint +6.7% Y/Y
Guided vs delivered
· last 5 settled
2024 revenue
2024
guided $110M
$113.69M
Beat +3.4%
2023 revenue guidance
2023
guided $130M
$130.38M
Beat +0.3%
Revenue
2022
guided $111M – $113M
$115.38M
Beat +3.0%
Revenue
full year 2021
guided $99M – $101M
$102.6M
Beat +2.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
+4%
Bullish
RSI (14)
66
Neutral
MACD trend
Positive
Bullish
52-week position
9%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +18 funds added
Insider flow
Accumulating
Net +$823.7K over 90 days · 75% sells
Short interest
Falling
4.73% of float · ▼ -1.3% MoM · 6.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
92 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $4 · 9%
Range high $16
vs 200-day avg -1%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Net cash used during the quarter | $9.5M | Q2 2026 | +6.4% |
|
|
|||
| Non-GAAP general and administrative expense non-GAAP | 17.13M | Six Months Ended June 30, 2026 | — |
| Non-GAAP gross margin non-GAAP | 43% | Six Months Ended June 30, 2026 | — |
| Non-GAAP gross profit non-GAAP | 25.57M | Six Months Ended June 30, 2026 | — |
| Non-GAAP net loss non-GAAP | $14.7M | Q2 2026 | — |
| Non-GAAP net loss per share, diluted non-GAAP | -$1.63 | Six Months Ended June 30, 2026 | — |
| Non-GAAP net loss, diluted non-GAAP | -30.15M | Six Months Ended June 30, 2026 | — |
| Non-GAAP operating expenses non-GAAP | $25.8M | Q2 2026 | — |
| Non-GAAP research and development expense non-GAAP | 9.65M | Six Months Ended June 30, 2026 | — |
| Non-GAAP sales and marketing expense non-GAAP | 24.56M | Six Months Ended June 30, 2026 | — |
| Non-GAAP total operating expense non-GAAP | 51.35M | Six Months Ended June 30, 2026 | — |
| Recurring revenue | $22.1M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OM
this stock
Outset Medical, Inc.
|
$57.33M | +10.5% | +5.1% | — | 4.7% |
|
ABT
Abbott Laboratories
|
$174.90B | -20.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -8.4% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -18.8% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.5% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OM | +38.5% | +14.2% | -5.8% | +36.7% | +10.5% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | +37.3% | +13.6% | -17.3% | +35.1% | -3.1% |